Try
Organon & Co.
OGNUnited States
44 filed reports · 446 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
44 reports · Mar 2021 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 105 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Current · 8-KSEC EDGAR | 19 | 103 | Jun 2021 to Dec 2025 |
| Quarterly · 10-QSEC EDGAR | 17 | 4,909 | Mar 2021 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 5 | 3,870 | Dec 2021 to Dec 2025 |
| Quarterly · 10-Q/ASEC EDGAR | 2 | 2 | Mar 2025 to Jun 2025 |
| Annual · 10-K/ASEC EDGAR | 1 | 703 | Dec 2024 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Jul 31, 2026 | 524 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 4, 2026 | 416 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 24, 2026 | 1,644 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Feb 12, 2026 | 6 | Open |
| FY2025 Q3 | 8-K | Sep 30, 2025 | Nov 10, 2025 | 8 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 10, 2025 | 409 | Open |
| FY2025 Q2 | 10-Q/A | Jun 30, 2025 | Nov 10, 2025 | 1 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 6, 2025 | 240 | Open |
| FY2025 Q2 | 8-K | Jun 30, 2025 | Aug 5, 2025 | 8 | Open |
| FY2025 Q1 | 10-Q/A | Mar 31, 2025 | Nov 10, 2025 | 1 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 2, 2025 | 247 | Open |
| FY2025 Q1 | 8-K | Mar 31, 2025 | May 1, 2025 | 7 | Open |
Financial data
446 concepts · 9,587 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial434 concepts · 5,873 facts · Dec 2019 to Jul 2026
- Cash cash equivalents restricted cash and restricted cash equivalents34 · Dec 2019 to Jun 2026
- Stockholders equity (US GAAP)34 · Dec 2019 to Jun 2026
- Adjustment for amortization33 · Dec 2019 to Jun 2026
- Allocated share based compensation expense33 · Dec 2019 to Jun 2026
- Comprehensive income net of tax33 · Dec 2019 to Jun 2026
- Cost of goods and services sold (US GAAP)33 · Dec 2019 to Jun 2026
- Deferred income tax expense benefit33 · Dec 2019 to Jun 2026
- Depreciation33 · Dec 2019 to Jun 2026
- Effect of exchange rate on cash cash equivalents restricted cash and restricted cash equivalents33 · Dec 2019 to Jun 2026
- Employee service share based compensation tax benefit from compensation expense33 · Dec 2019 to Jun 2026
- Foreign currency transaction gain loss before tax33 · Dec 2019 to Jun 2026
- Income tax expense benefit33 · Dec 2019 to Jun 2026
- Increase decrease in accounts payable trade33 · Dec 2019 to Jun 2026
- Increase decrease in accounts receivable33 · Dec 2019 to Jun 2026
- Increase decrease in accrued income taxes payable33 · Dec 2019 to Jun 2026
- Increase decrease in accrued liabilities33 · Dec 2019 to Jun 2026
- Increase decrease in inventories33 · Dec 2019 to Jun 2026
- Increase decrease in other current assets33 · Dec 2019 to Jun 2026
- Increase decrease in other operating capital net33 · Dec 2019 to Jun 2026
- Net income loss33 · Dec 2019 to Jun 2026
- Other comprehensive income defined benefit plans adjustment net of tax portion attributable to parent33 · Dec 2019 to Jun 2026
- Other comprehensive income foreign currency transaction and translation adjustment net of tax portion attributable to parent33 · Dec 2019 to Jun 2026
- Other comprehensive income loss before tax portion attributable to parent33 · Dec 2019 to Jun 2026
- Other comprehensive income loss net of tax33 · Dec 2019 to Jun 2026
Product1 concepts · 3,365 facts · Dec 2019 to Jun 2026
- Revenue3,365 · Dec 2019 to Jun 2026
Geography5 concepts · 245 facts · Dec 2019 to Jun 2026
- Revenue231 · Dec 2019 to Jun 2026
- United States6 · Dec 2020 to Dec 2025
- Loss contingency damages sought value4 · Dec 2022 to Jun 2023
- Income tax reconciliation tax settlements foreign2 · Dec 2023
- Switzerland2 · Dec 2023
Guidance5 concepts · 103 facts · Aug 2021 to Feb 2026
- Revenue Guidance38 · Aug 2021 to Feb 2026
- Effective Tax Rate Guidance36 · Aug 2021 to Feb 2026
- Gross Margin Guidance20 · Aug 2021 to Feb 2026
- Free Cash Flow Guidance5 · Aug 2024 to May 2025
- Revenue Growth Guidance4 · Aug 2025 to Nov 2025
Segment1 concepts · 1 facts · Dec 2025
- Goodwill transfers1 · Dec 2025
Segments
3,611 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or service45 members · 3,365 facts
- Arcoxia99 · Dec 2019 to Jun 2026
- Atozet99 · Dec 2019 to Jun 2026
- Brenzys99 · Dec 2019 to Jun 2026
- Clarinex99 · Dec 2019 to Jun 2026
- Cozaar Hyzaar99 · Dec 2019 to Jun 2026
- Diprospan99 · Dec 2019 to Jun 2026
- Dulera99 · Dec 2019 to Jun 2026
- Follistim AQ99 · Dec 2019 to Jun 2026
- Fosamax99 · Dec 2019 to Jun 2026
- Nasonex99 · Dec 2019 to Jun 2026
- Nexplanon Implanon NXT99 · Dec 2019 to Jun 2026
- Ontruzant99 · Dec 2019 to Jun 2026
- Other Non Opiod Pain Bone And Dermatology99 · Dec 2019 to Jun 2026
- Other Sundry Established Brands99 · Dec 2019 to Jun 2026
- Propecia99 · Dec 2019 to Jun 2026
- Proscar99 · Dec 2019 to Jun 2026
- Renflexis99 · Dec 2019 to Jun 2026
- Singulair99 · Dec 2019 to Jun 2026
- Vytorin99 · Dec 2019 to Jun 2026
- Zetia99 · Dec 2019 to Jun 2026
- Nuva Ring98 · Dec 2019 to Jun 2026
- Other Cardiovascular98 · Dec 2019 to Jun 2026
- Other Sundry Products98 · Dec 2019 to Jun 2026
- Other Respiratory97 · Dec 2019 to Jun 2026
- Other Womens Health97 · Dec 2019 to Jun 2026
- Rosuzet97 · Dec 2019 to Jun 2026
- Hadlima84 · Dec 2020 to Jun 2026
- Marvelon Mercilon72 · Dec 2020 to Jun 2026
- Aybintio69 · Dec 2020 to Jun 2025
- Other Biosimilars66 · Dec 2019 to Jun 2026
- Ganirelix Acetate Injection63 · Dec 2021 to Jun 2026
- Jada63 · Dec 2021 to Jun 2026
- Orgalutron54 · Dec 2019 to Jun 2023
- Emgality Ravvow51 · Dec 2022 to Jun 2026
- Cerazette42 · Dec 2019 to Sep 2022
- Vtama42 · Dec 2022 to Jun 2026
- Asmanex33 · Dec 2019 to Dec 2021
- Diprosone33 · Dec 2019 to Dec 2021
- Sinemet33 · Dec 2019 to Dec 2021
- Zocor33 · Dec 2019 to Dec 2021
- Remeron32 · Dec 2019 to Dec 2021
- Emgality Rayvow9 · Dec 2022 to Dec 2024
- Other Non Opioid Pain Bone And Dermatology9 · Dec 2022 to Dec 2024
- Bildvos Bilprevda6 · Jun 2025 to Jun 2026
- Tofidence6 · Jun 2024 to Jun 2025
Statement geographical9 members · 245 facts
- US39 · Dec 2019 to Jun 2026
- Asia Pacific And Japan33 · Dec 2019 to Jun 2026
- CN33 · Dec 2019 to Jun 2026
- Europe And Canada33 · Dec 2019 to Jun 2026
- Latin America Middle East Russia And Africa33 · Dec 2019 to Jun 2026
- Non Us33 · Dec 2019 to Jun 2026
- Other Countries33 · Dec 2019 to Jun 2026
- CH4 · Dec 2023
- ES4 · Dec 2022 to Jun 2023
Statement business segments1 member · 1 facts
- Operating1 · Dec 2025
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.